Trial Profile

A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ELVN-001 (Primary)
Indications Chronic myeloid leukaemia
Focus Adverse reactions; First in man; Proof of concept
Acronyms ENABLE
Sponsors Enliven Therapeutics

Most Recent Events

08 Jan 2026 According to an Enliven Therapeutics media release, mid-year presentation of additional Phase 1 data from this trial is an expected clinical milestone in 2026.
08 Jan 2026 Results published in the Media Release
03 Nov 2025 According to an Enliven Therapeutics media release, company announced As of the cutoff date of April 28, 2025, six patients with previously treated chronic phase CML who had an atypical transcript received ELVN-001 at doses from 20 mg to 80 mg twice daily (BID) in the dose escalation phase of the ENABLE study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com